Bayer credits high quality of Pharmatest after joint publication of results for their FDA approved new cancer drug Xofigo
Pharmatest Services Ltd (Pharmatest) has been the preferred provider of Bayer Pharma AG (Bayer) since 2010. The results of several projects performed at Pharmatest regarding the newly FDA approved cancer drug Xofigo were published last week, and Bayer says to be impressed about the high quality of the work performed by Pharmatest during the collaboration.
Pharmatest offers clinically predictive preclinical efficacy services for the pharmaceutical industry for testing their drug candidates in the fields of oncology and skeletal diseases. Pharmatest has been the preferred provider of Bayer since 2010, after several years of successful collaboration.
During the past years Pharmatest has performed several projects for Bayer related to their new cancer drug Xofigo (radium-223 dichloride) that was approved by FDA last week for treating bone metastases in castration-resistant prostate cancer. Results of the projects were published jointly last week in Journal of the National Cancer Institute (impact factor 13.76) in a paper that demonstrates efficacy of radium-223 dichloride also for bone metastases in breast cancer.
Dr. Karl Ziegelbauer, Senior Vice President of Global Drug Discovery, TRG Oncology/GT at Bayer says: “Bayer has worked for several years with Pharmatest and we are very impressed about the high quality of the work they have done for us.”
Jussi Halleen, CEO of Pharmatest comments: “This new publication will be important for Pharmatest in convincing potential new customers about the high quality and clinical predictivity of the services that we offer. I want to thank Bayer for the trust and confidence in Pharmatest being able to perform these very important studies for them.”